【TOPGLOV 7113 交流专区】顶级手套

JeanGrey

基本法也是有Cut-loss point的。
人家没有提到，不是说没有。
（提示：明知道美元会下跌，为什么你们所谓的基本派师傅、股神巴菲特会在当时减少他对美元的看空呢？）

如果你稍微知道箱子型运作的图表分析，那么你不难就会知道基本派也有同样的切入点。书本写什么，你就相信什么。那么每一本书就是圣经了！

Mr.Business

股价比一比。。。

TOPGLOV
(7113) 11:24:28
Last Done        4.700
Change        -0.020
Day High        4.700
Day Low        4.680
Best Buy        4.680
Best Sell        4.700
Volume(Lot)        129


SUPERMX
(7106) 11:24:28
Last Done        1.570
Change        0.000
Day High        1.600
Day Low        1.570
Best Buy        1.570
Best Sell        1.580
Volume(Lot)        1258


KOSSAN
(7153) 11:23:28
Last Done        3.420
Change        -0.140
Day High        3.420
Day Low        3.420
Best Buy        3.500
Best Sell        3.520
Volume(Lot)        4

Mr.Business

原帖由 scsiang82 于 6-3-2008 09:52 AM 发表
此外，香港公司Eco手套發明了將手套循環的科技--Tr@ce。有關的科技能降低營運成本高達30%。

http://eco-glove.org/index.html

Mr.Business

这是2003年的旧闻，文中说天然胶手套占了世界手套市场的80％，不知道这资料还准确吗？

Latex rubber gloves gaining popularity over synthetic rival
17 February, 2003

Latex rubber gloves are fast gaining popularity over the synthetic rubber-based competitor due to rising cost in the latter’s main raw material — crude oil.

Latex rubber gloves’ main raw material is natural rubber (NR) and have a global market share of about 80%, while synthetic rubber gloves — made up of either nitrile, vinyl or polyvinyl chloride (PVC) gloves — have a share of almost 20%.

Malaysian Rubber Glove Manufacturers’ Association President, James Liew, said the recent prices of oil have also seen a corresponding increase in the price of synthetic gloves.

“This alone will negate any price advantage they have enjoyed over the past few years and on top of all these, there is also the environmental issue where synthetics have big problems. The Germans have had very bad experience with PVC and to date are still suffering from its effects,” said Liew.

Top Glove Corp Bhd President and Managing Director, Dr Lim Wee Chai, said global consumers may change their preference to NR gloves over synthetic in the near term.

“There has been significant price increase in PVC gloves while nitrile glove prices are still stable, but we have to wait and see because both NR and synthetic glove prices fluctuate according to supply and demand conditions.

However, the consumption of both NR and synthetic gloves will gain 5-8% annually in line with global demand and population growth.”

Malaysia is the world’s biggest producer of NR gloves in the past 10 years, and sold 22.8 billion pieces in 2000 valued at RM3.4 billion.

About half of its exports goes to the US for household, surgical, industrial and other uses.

Adapted from "Business Times", 17 February, 2003

http://www.mida.gov.my/beta/news/print_news.php?id=215

Mr.Business

旧闻

The Surgical Glove Market in Europe: Key players

Date Published: 27 Nov 2004
By Kavitha Ravikumar, Medical Devices Research Anlayst.

The measurement of excellence may be controversial, but it is a benchmark in most cases. The ability to perform under tough conditions, use the market drivers to the maximum, overcome restraints, measure up and often surpass expectations and challenges are often the qualities that mark excellence.

The surgical glove market in Europe is in its mature stage. There is a wide awareness of allergy issues to the latex content of the gloves and in some cases to the chemicals and additives of the synthetic gloves. The healthcare sector in Western Europe is facing budget cuts. Most government run agencies as well as private hospitals and organisations are looking at streamlining process as well as cutting corners in terms of costs. The main trend for the growth of this market is the replacement trend. This trend is seen to a large extent in powdered to powder free surgical gloves and to a smaller extent in natural rubber latex to synthetic (latex free) surgical gloves.

So who has made a mark on the surgical glove market in Western Europe? The concentration of the market in terms of large players is high but as with most mature market, innovation and differentiation play key roles in cornering both market share and brand recall.
Regent Medical Ltd. is a recent formation that purchased the assets of Regent Biogel and the Hibi business from SSL International. The Biogel range is very popular in the powder free latex glove market in the United Kingdom and Scandinavia. Regent commands respect for its stand on allergy issues and dedication to providing the finest quality of powder free latex gloves. It inspires high levels of loyalty in its users. Regent has thus effectively capitalized on the powdered-to-powder-free conversion trend. Known for its high standards of quality control, Regent also has high brand recall. Launching of latex allergy support packs, workshops on surgeries and surgical education, guidelines and research papers are also part of the services Regent Medical offer as value addition on customer services.

Ansell Limited on the other hand has a broader base of operations. It was formerly known as Pacific Dunlop Ltd and has 31 facilities in 16 countries worldwide with an employee base of 12,000 people.    Ansell Limited has products in all the three major segments of the surgical gloves market. They have one of the widest ranges of gloves. More than one third of their sales comes from products that have been on the market for three years or less. A broad product range, a wide distribution network a large sales team of professionals is their magic combination. To deal with the challenges in the current market scenario, Ansell has come up with the ‘Glove Management Program’ and the ‘Ansell cares’ program.  The company is widely admired in the market for its strong presence and customer focus.

The Medical Products and Services business of Cardinal Health is the section that deals with surgical gloves. Cardinal aims at providing maximum comfort to users by designing gloves that fit and feel better. Customer satisfaction through differentiation innovation has been Cardinal’s motto. Cardinal’s products have the edge of luxury with practicality. Differentiating and innovating to suit customer preferences to keep up with market trends has been cardinal’s strong suit.

Hutchinson is a world leader in the industrial rubber sector. Operating mainly in Europe, the Americas and Asia, Hutchinson at the end of 2002 was the employer of 24,820 people in 145 manufacturing and sales establishments in 31 countries. Hutchinson has demonstrated its strong suit in research and development many times. It has had an emphasis on sustainable development and has come up with increasingly innovative and unique products. They now enter the surgical gloves market with their new G-VIR Surgical Gloves. This advanced glove is a result of ten years of concentrated research.

ECI Medical Technologies Inc. is a leading manufacturer of synthetic (polyisoprene) surgical gloves. Polyisoprene is viewed as the material of the new surgical glove generation and ECI is looking to create a substantial market for its products in Europe. Their gloves do not contain irritants and allergens like accelerator chemicals and chlorination. It is manufactured in a latex-free environment. ECI hopes to capitalise on the conversion from Latex to synthetic (latex free) surgical gloves.

These five have been recognised by Frost & Sullivan for market leadership, penetration leadership, differentiation innovation, and technology innovation and entrepreneurship qualities. Sempermed Inc., a company that is worth watching is rapidly increasing its market share. Other significant companies in the field include BSN medicals, Hartmann Group and B Braun Melsungen AG.

It has been anticipated that the fast ageing population and the increase in surgical procedures would drive demand. Double gloving has been suggested as another possible driver. But with minimally invasive surgery, decrease in surgical procedures to reduce trauma and decreased stay of patients in hospitals, the trend has been one of constant demand.

The main driver for revenue increase is projected to be the total replacement of powdered gloves by powder free gloves and a part of the powder free gloves market by an increase in demand for synthetic gloves. This is because the powder free gloves are more highly priced compared to the powdered surgical gloves. The synthetic gloves are priced the highest. Research is ongoing on the synthetic material used in these gloves so as to maximise comfort, flexibility and protection. There is still room for innovation in the market and future technology, pricing and positioning should shape the market in the next decade.

http://www.frost.com/prod/servle ... .pag?docid=28354323

Mr.Business

旧闻

Anti-allergy efforts loosen latex's grip on glove market.

From: Healthcare Purchasing News
Date: 5/1/2000
Author: Williamson, Julie E.



Manufacturers of natural rubber latex gloves should continue to hold a dominant share of the disposable medical exam glove market, despite growing concern about latex allergies in the healthcare environment. But natural latex's grip is slipping a bit, according to a new report.

In 1999, latex gloves captured 84% of the glove market. Revenues of $854 million, however, marked a 3% decline from 1998 totals. Synthetic gloves, meanwhile, made up the difference, bringing in $160 million, according to a report from Frost & Sullivan, San Jose, CA.

Two factors are driving the latex glove market. Safeskin Corp., San Diego, recently acquired by Kimberly-Clark Corp., Roswell, GA, added a new low-cost facility in Thailand, which has increased latex glove volume, adding millions of units to the U.S. market each year. In addition, glove manufacturers are supplying more powder-free exam gloves to meet growing demand "due to latex sensitivity," according to Frost & Sullivan researchers.

Anti-allergy efforts push change

But that's not to say synthetics won't capture more of the market in upcoming years. In fact, by 2006, their market share is projected to reach 21%. Latex glove revenues are forecasted to fall to 79%.

The reasons for the gradual shift primarily have to do with heightened latex allergy awareness, experts say. Over the past several years, an increasing number of healthcare facilities have responded to employee concerns by shying away from latex and powdered gloves, as well as other latex-containing products.

Toronto's St. Michael Hospital is one example. In 1995, the 450-bed tertiary care facility implemented a hospitalwide powder-free environment and began stocking latex-free alternatives to individuals who needed them.

"We knew that latex allergies are a potential problem for healthcare workers, so we decided we wanted to make some changes to reduce those risks," said infection control practitioner Susan MacMillan. "In addition to powder-free [products], we also keep latex-free kits in the operating room and emergency department."

And cost doesn't appear to be much of a deterrent. Although latex-free alternatives cost two cents more per pair on average, preventing just one latex allergy can make it all worthwhile, MacMillan said. After all, treating latex allergies can result in lost workdays and costly workers' compensation, she explained.

"Even though alternatives can cost more at the onset, we believe that they will more than pay for themselves in the long run," she said.

Agency involvement

The gravitation toward latex-free gloves will likely increase now that federal agencies are taking a more active role in latex-allergy prevention.

The National Institute of Occupational Safety and Health and the Centers for Disease Control and Prevention, Atlanta, recently issued guidelines for the prevention of allergic reactions to natural rubber latex in the workplace.

And the Food and Drug Administration hopes to add to the information bank. The agency's proposed rule to set maximum levels of protein and powder content of latex gloves and require manufacturers to label those contents will take effect sometime this spring.

The agency discovered that powder levels range anywhere from 70 mg to 350 mg per surgical glove and from 50 mg to 426 mg per patient examination glove. The rule would set a recommended powder limit of no greater than 120 mg of powder per glove.

The agency estimated that its recommendation could eventually reduce allergic episodes from a current 43,500 cases to just 1,000 cases per year.

http://www.encyclopedia.com/doc/1G1-65071725.html

Mr.Business

旧闻

Three players still dominate surgical glove market - Operating Room

Curt Werner
June 2003

When the time comes to talk about standardization and finding allies among physicians, one of the product areas that is likely to make those physicians battle back is surgical gloves, No wonder. For surgeons to do their life-saving work, they must wear gloves each day that offer them a distinct feel, comfort and grip while giving them confidence that their job is being done correctly and safely. For all the multi-million dollar equipment found in the modem operating room, the surgical glove is, to borrow a phrase, where the rubber meets the road.

Satisfying tough demands from surgeons regarding surgical gloves is no simple matter. Nor is doing it cost-effectively in a highly competitive industry segment. Manufacturing processes are much more difficult and costly for surgical gloves than for their cousins, examination gloves. Those factors go a long way toward explaining why just three surgical glove manufacturers hold near complete domination over the market.

The exam glove market should not be confused with the surgical glove market. In the former, literally scores of suppliers large and small (some actually call themselves manufacturers when in reality they are distributors or dealers) vie for thin slices of market share and compete mostly on price, selling items that cost less than a dime. Surgical gloves cost ten or twenty times more than exam gloves, are designed for longer wear, sensitivity and fit and are of much higher quality, among other significant differences.

The three surgical glove powers are Ansell Professional Healthcare, now based in Red Bank, NJ, after moving its headquarters from Massillon, OH, last year; Cardinal Health, McGaw ark, IL; and Regent Medical, a British-owned firm based in this country in Norcross, GA. By most estimates, approximately 93 out of every 100 pair of surgical gloves sold in the U.S. are manufactured by one of these three. More precisely, generally accepted fourth quarter 2002 figures for total surgical gloves give Regent and its popular lines of Biogel gloves the lead with a 36.3 percent share, followed by Cardinal and its several brands at 31.8 percent and Ansell, which acquired the surgical glove unit of Johnson & Johnson a few years ago, holding a 25.8 percent U.S. share.

A slew of other companies are battling for the remaining market share. Among them are Sempermed USA, Palm Harbor, FL; Maxxim Medical, Clearwater, FL; Medline Industries, Mundelein, IL, and Kimberly-Clark Professional, Roswell, GA, a company that "re-launched" its Safeskin surgical glove line earlier this year with hopes of eventually breaking the three-company logjam at the top.

As for dollars, the latest figures from IMS provided to Healthcare Purchasing News by Cardinal Health place the U.S. market for surgical gloves at $302 million, with $211 million of those sales coming from acute care facilities. The remaining $91 million came from alternate site facilities, including a growing market in surgicenters and so-called surgical hospitals. The latter category includes facilities that are designed for stays of no longer than 72 hours and are generally used for simpler procedures that usually lead to fewer complications than the full-scale surgical procedures performed in acute care hospitab. The IMS figures show 385 million units sold in this country, with some 68 percent used in hospitals. The market is growing in the low single-digits, 2-3 percent annually, though there is some fluctuation from year to year, and what growth there is in the market today remains relatively modest by most standards, and is naturally tied to the number of surgeries performed.

In a highly competitive marker, there could soon be a major change at the tap. This spring, blaming sluggish sales, SSL International, the UK corporation that produces Dr. Scholl footwear and Durex condoms, announced plans to sell its Regent Medical division (which includes the Hibistat germicidal product lines as well as Biogel gloves). As this is bring written in early May, no deal has been announced and no potential suitors have emerged for Regent, but the speculation among glove-makers is tantalizing. For its part, SSL says it plans to use the proceeds of the sale "to reduce debt and invest in the development of the consumer business." But until a buyer steps forwards, a development that could redraw the lines in the surgical glove market or herald the entry of a new player, the market moves along as is.

Regent Biogel still taps the market

For the past few years, the market for surgical gloves has been edging in the direction of powder-free non-latex products, and that development is continuing today. The market leaders have capitalized on the trend as they seek new technologies that simulate the feel of natural rubber latex while retaining the safety of a synthetic glove product. Recent sales slowdown aside, Regent Medical appears to have capitalized the most over the years from surgeons' demand for powder-free non-latex gloves. The company, in fact, produces no other type glove. "We were the lone voice in the wilderness calling for powder-free surgical gloves," says Dan Manley, vice president of marketing for Regent. The company entered the U.S. market in the early 1990s. He believes that today, the shift to powder-free non-latex "continues and may have accelerated" while reporting volume growth for powder-free products and stronger growth rates for non-latex versions on a smaller base.

In a tight economy, pressure from hospitals to cut costs has been relentless, and unrelenting on glove makers just as it is on manufacturers in other segments. But cost is not a place where Regent or the other players want to compete. That places heightened pressure to spend more on research and development, along with parallel pressures to offer something new to users. Regent has devoted funds to improving the fit and feel of its surgical gloves. Its most recent product launch was the March debut of the Biogel Skinsense PI. Calling the new product, which augments an earlier Skinsense line, "a significant breakthrough in surgical glove technology," Manley says the new synthetic glove closely mimics a natural rubber latex product. "Synthetic glove users used to complain about a 'dead' feel, like the feel you get from kitchen gloves," says Manley. "The new glove addresses that complaint. Users love them because they are similar to natural rubber latex." The Skinsense PI is the third adaptation of its synthetic latex glove.

Regent was scheduled to launch another glove this spring. Known as Optifit, the new gloves aimed at wearers of newer lines of surgical gowns that are made with impervious materials. Optifit gloves are designed to prevent the kind of "slipdown" of gloves that commonly occur with these gowns.

As much as they disdain competing on price, surgical glove manufacturers are forced to respond to price pressures. So thanks to tough market competition and hardnosed bargaining by group purchasing organizations average selling prices for surgical gloves have been flat or even in decline. Manley believes that the price slump has slowed, however, and that the decline in the powder-free segment "has stopped."

Cardinal sales surge

Although it holds second place in the surgical glove market, there are few manufacturers in any segment more imposing than Cardinal Health. No longer known in most markets as Allegiance and tracing its roots to powerhouse Baxter International and before that American Hospital Supply, Cardinal is as competitive as any outfit around and, in constant search of more market share, is unafraid to launch a range of new products in the many markets it touches, including med-surg and pharmaceutical distribution.

With Regent for sale, watch for Cardinal to nip even closer at that company's heels as it seeks to close the roughly four-point market share gap. "Our business is exploding," says Jeannie Thomas, the company's vice president of marketing for medical gloves. "We now have the highest growth rate in the industry and a big part of that is with our new products." According to Thomas, Cardinal's surgical glove sales are growing at a rate four times that of the rest of the market with venerable brands such as Duraprene and newer ones like Esteem leading the way.

Thomas says that sales of synthetic surgical gloves surged by 65 percent in 2002, a rate she says is double that of the rest of the category. However, unlike Regent, the company still produces a large supply of powdered surgical gloves to meet trailing demand. Although Cardinal has released no new powdered surgical glove products, Debra Schotz, a company spokesperson, says that despite the big move in favor of powder-free, approximately half the overall market still uses powdered gloves.

Thomas says there is still "pent-up demand" for quality synthetic surgical glove products. Cardinal is, of course, ready and willing to meet that demand even as hospitals steel themselves for the higher prices on newer synthetic products like the new Esteem glove. Patient and worker safety are winning out over price considerations. "Customers don't seem to be overly concerned about price because they see other advantages to using latex-free products," says Schotz. She says that some hospitals are moving house-wide to the new Esteem glove.

Thomas says that prices for powdered latex gloves have decreased for the last few years and that even more recently, prices in that segment have fallen further as users drift toward powder-free non-latex gloves and competition grows in the powdered glove segment to fill the vacuum.

Yet, despite the talk and the hype about synthetics, changes in surgeons' gloving habits are slow, and more than 90 percent of users still don natural rubber latex gloves. "People are not as willing to change their surgical gloves," says Thomas, which is one reason why the market stacks up the way it does and few companies are willing to make the investments necessary to enter it.

Tough times behind it, Ansell senses better days ahead

The fact that market share in a physician preference segment like surgical gloves is so precious and so difficult to win makes the market slump that has hit Ansell Professional Healthcare even tougher to take. The company, which acquired the glove unit of Johnson & Johnson a few years ago, has shed several points in the last two years. Donna Hatcher, a former Cordis and Boston Scientific executive who was recently named Ansell's business development manager, acute care, admits the state of affairs is harsh. But she is quick to point out that Ansell is working hard to reverse the fortunes of a glove brand that still has plenty of respect among surgeons.

Before its recent difficulties, Ansell had just under a 30 percent share; that number has since slipped to under 26 percent. Why? "Supply has become our main issue," Hatcher concedes. "But we are rapidly coming back."

So deep was the slip that the company has embarked on some radical steps to remedy the situation. Chief among them was scuttling its old headquarters in Massillon, OH, last year and moving almost everything to Red Bank, NJ, not far from New York City. "We feel it is more effective and more efficient to have our corporate headquarters in one spot," she says. Ansell operated its consumer lines, consisting mainly of condoms, from Red Bank before the move. The reorganization also swept out old management and brought in new, including freshly named executives in supply chain operations, global marketing and science and technology. "We are looking ahead and moving forward," says Hatcher. "Clearly our biggest chore is making sure our supply situation is straightened out after our transition period of moving to New Jersey." With all those new faces in place and the new plant open and running, next on the agenda is revitalizing the brand. "We have an extremely diverse product line, including both exam and surgical gl oves," says Hatcher. The J&J acquisition grew the business, but so did the earlier acquisition of the Perry glove line, and the company now boasts a stable of surgical gloves with names such as Dermaguard, Derma Prene, Encore and Micro-Touch.

Like its competitors, Ansell sees growth in its powder-free surgical glove sales, so it's not surprising that the company has dispatched clinical specialists across the country to spread the gospel of powder-free products. But also like its competitors, Ansell has been dogged by low prices, which are good news for hospitals, but not exactly the vaccine a recovering company like Ansell needs. Says Hatcher, "The glove industry is trying to get its arms around appropriate pricing for gloves that offer the next step beyond latex. But we are very sensitive to our customers' needs and to the basics of offering gloves that have maximum protection and maximum sensitivity. We have new talented people, have fortified our infrastructure, changed our communications with our customers and we are seeking to expand our markets. I have to say that I'm bullish on Ansell."

http://findarticles.com/p/articles/mi_m0BPC/is_6_27/ai_103088254

Mr.Business

旧闻

Monday April 23, 2007

Top growth for gloves

In the manufacturing industry, the natural rubber glove sub-sector continues to show promise.  

Earlier this month, Top Glove Corp Bhd offered guidance that its earnings growth would still be at relatively high double-digits over the next three years.

Two brokerages said last week they expected Kossan Rubber Industries Bhd would also continue to rapidly expand over the next three years. This was their top pick in this sector.  

CIMB Research raised its target price for Kossan to RM7.20 while BNP Paribas sets its target of RM7.40. The stock closed at RM5.40 last week.  

Kossan's share price has climbed 125% from RM2.40 a year ago to its current price, an excellent return on investment by any measure.  

Foreign fund managers supported this increase in its value.  

Its foreign shareholding, it is understood, rose from just 3% a year ago to about 15% last month.  

That still has a lot of room to expand.  

The case for Kossan is quite simple. Its earnings are forecast to expand at an annual clip of 25 to 30% during these three years, and its shares traded at an inexpensive price/earnings ratio (PE) of about 15 times this year.  

If it can maintain its PE, its share price can move up 25 to 30% a year on just its earnings growth.  

Both CIMB and BNP expect that Kossan's PE valuation would also expand. That would occur if foreign funds continue to flow into the stock.  

Presently, most brokerages cover only the Big Three namely, Top Glove, by far the largest with a market value of RM2.7bil, Kossan (RM860mil) and Supermax Corp Bhd (RM570mil). All three mainly produce examination gloves used in medical clinics and hospitals.  

There is one glove company, Adventa Bhd that is so small it is a blip on the radar screens of investors.  

Its market value is less than RM140mil but it is one of the world's largest manufacturers of surgical gloves.  

This is an important year for Adventa because it is understood it is doubling its plant capacity.  

In a note last month, Standard & Poor's forecast the company's net profit to surge 40% to RM21.5mil in its current financial year ending Jan 31, 2008 and another 40% to RM30.5mil next year.  

Adventa's shares at RM1.08 each would be valued at a PE of just 6.3 times this year and 4.5 times next year.  

That's very undemanding for a growth stock.  

There were already indications that Adventa had gotten onto a fast track.  

Its revenue shot up 74% in its fourth quarter ended Jan 31, 2007 while pre-tax profit rose 170% to RM7.2mil.  

Its net earnings could not be compared, as taxation was positive in the previous period.

http://thestar.com.my/news/story ... 505524&sec=business

[ 本帖最后由 Mr.Business 于 7-3-2008 12:36 PM 编辑 ]

Mr.Business

出口商的痛苦。。。

美減息機率大‧馬幣挺升至3.1800新高

2008-03-06 12:04

（吉隆坡）美國聯邦儲備局減息機率看好，全球投資者看淡而猛拋美元，致使區域貨幣今日（週三，5日）普遍走高，馬幣兌美元一度挺升0.3%至3.1805水平，為1997年10月以來最高水平。

馬幣在過去1週已上漲了1%，一名交易商指出，目前持有馬幣的回酬率絕對勝於投資美元。

即將出爐的2月份美國消費數據，備受全球投資者關注之際，馬幣連續兩個交易日挺漲，分析員普遍估計美國供應管理學院數據將下滑，市場普遍臆測聯儲局將大手降息挽回投資者信心，加重美元跌勢。

惟分析員擔心區域貨幣的強勁走勢，或引起各國中行入場干預，避免匯率升高打擊競爭力，同時不排除部份貨幣的增幅已至中行允准的底限。

肯納格投資銀行的經濟學家旺蘇海米說，馬幣仍有增至空間，外資熱錢流入將持續推高馬幣，同時區域中行也樂以維持較強勁的貨幣政策以控制通膨。

與此同時，市場普遍看好原產品的強勁需求，將推動原產品出口並扶持大馬經濟，減少美國經濟放緩的衝擊，也支持馬幣匯率延續堅挺。

星洲日報／財經‧2008.03.06

XXXXX

馬幣升至3.1655高水平

2008-03-06 18:23

（吉隆坡）由於市場看好大馬和美國的利差會擴大，加上預料大馬成長前景會引資金入，馬幣連續第三天升值，今日（週四，6日）一舉衝破3.17水平，來到3.1655令吉的10年新高，是1997年10月以來最高值。

馬幣今日一開市就升破3.18水平，最高升至3.1660，升0.5%；昨日報3.1823。截至下午5時，馬幣掛3.1665。

馬幣今年已升值4.2%,在亞洲10種最活絡貨幣中（日圓除外）排第二。市場料美國本月18日會再降息，而國家銀行料保持利率不變於3.5%，馬美的利差優勢會擴大。

交易商預期美國聯儲局會再下調利率0.5%至2.5%，在國行不調息下，馬美利差是2006年5月以來最高溢價。

另外，大馬的經濟成長前景受看好，也令市場“賭”馬幣會繼續升值，因為資金會繼續流入大馬。今日大馬公佈1月出口加速成長，達10.4%，是3個月新高，也遠遠超出市場預測的5%至5.7%成長。

大馬評估機構的首席經濟學家姚金龍表示：“大馬和美國的利差預料會擴大，給馬幣助力，經濟成長前景穩定也為馬幣中期帶來支撐。”他看好至年底馬幣兌美元會升至3.10水平。

星洲日報／財經‧2008.03.06

chengyk

马币升值将不利顶级 !!!

悶蛋

所以就再等，3.**不是梦

hancom

RM0.50可以吗？

悶蛋

没问题，等audit宣布工厂的机器全都不见了

thierry_henry

真的是那句:do not catch a falling knife?

invest_klse

上面 #1166 和 #1168 楼的旧闻中，有间叫 Cardinal Health 的，它是 Spolymer 的大顾客哦。

三年前，Spolymer 的 IPO 中，有这么个资料：

tan81

对不起，没有跟进。什么关系？ 不大看得懂。

invest_klse

原帖由 tan81 于 7-3-2008 11:38 PM 发表
对不起，没有跟进。什么关系？ 不大看得懂。

其实跟 Topglov 没直接关系啦，

Spolymer 是 Supermx 的子公司。
因为在这里看到那篇旧闻，所以我就在这里回复咯。

悶蛋

topglove咸鱼翻身，目前暂时名列十大上升股

悶蛋

好啦，invest_klse，你等的4.50到了，
怎么样，有打算再等吗

hancom

五毛钱。。。。